CNBC's Jim Cramer on Friday explained how he might navigate the market in this turbulent economic environment.

This was the stock's second consecutive day of gains.

BofA analyst Allen Lutz raised the firm’s price target on Cencora (COR) to $285 from $270 and keeps a Neutral rating on the shares. The recent ...

BofA raised the firm’s price target on McKesson (MCK) to $755 from $665 and keeps a Buy rating on the shares. The recent introduction of ...

Shares of Cencora Inc. COR rose 1.92% to $279.15 Thursday, on what proved to be an all-around grim trading session for the ...

The article " Top 3 S&P 500 Winners in a Losing Market " first appeared on MarketBeat.

We came across a bullish thesis on Cencora, Inc. (COR) on Substack by Hidden Market Gems. In this article, we will summarize ...

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

The potential for cell and gene therapies is growing, offering groundbreaking treatments for rare genetic disorders and ...

Walgreens Boots Alliance reported stronger-than-expected second-quarter earnings Tuesday as the pharmacy chain accelerated ...

Pharmaceutical companies accused of fueling the nation's opioid crisis are paying state and local governments billions of ...

The company is in the process of being taken private by Sycamore Partners in a deal that is expected to close in the fourth ...